加味益肾活血方对慢性肾脏病5期患者肠道微生态的影响

桂志红; 黄刚; 王华富; 兰乐健; 吴凌慧; 许伟海; 廖益飞; 彭健韫

加味益肾活血方对慢性肾脏病5期患者肠道微生态的影响

1.
丽水市人民医院肾内科，浙江丽水 323000
2.
丽水市人民医院临床药学科，浙江丽水 323000

计量
- 文章访问数: 616
- HTML全文浏览量: 7
- PDF下载量: 643
- 被引次数: 0
出版历程
- 刊出日期: 2019-05-10

Effects of Yishen Huoxue Decoction on Intestinal Microecology in Patients with Chronic Kidney Disease Stage Ⅴ

1.
Department of Nephrology, Lishui People's Hospital, Lishui, 323000, China
2.
Clinical Pharmaceutical Department, Lishui People's Hospital, Lishui, 323000, China

摘要

摘要: 目的观察加味益肾活血方对慢性肾脏病（CKD）患者肠道菌群微生态紊乱的影响。方法以本院收治的CKD 5期中医辨证属于脾肾气虚、湿浊瘀血内阻的非透析患者为研究对象，随机分为2组，治疗组45例，对照组38例。对照组采用常规治疗，治疗组常规治疗加用加味益肾活血方口服。8周后采集CKD患者的血标本和粪便标本，采用PCR测定粪便中乳酸杆菌、双歧杆菌、大肠杆菌、粪肠球菌的菌群浓度；应用全自动生化仪检测常规生化指标，包括血红蛋白（Hb）、总蛋白（TP）、白蛋白（Alb）、肌酐（Scr）、尿素氮（BUN）等；ELISA法检测微炎症指标浓度。分析2组治疗前后主要症状积分、肾功能、微炎症指标、肠道微生态的变化。结果治疗后治疗组Scr、BUN水平有所下降，超敏C反应蛋白（hs-CRP）、白介素-6（IL-6）、肿瘤坏死因子（TNF-α）浓度下降(P<0.05)，与对照组比较有显著性差异（P<0.05~0.01）。2组主要证候积分均有下降(P＜0.05)，但治疗组优于对照组(P＜0.05~0.01)。治疗组肠道内有益菌群如乳酸杆菌、双歧杆菌属细菌浓度显著升高(P＜0.05)，而肠道内有害菌如大肠杆菌和粪肠球菌属浓度均显著降低(P＜0.05)，与对照组比较有显著性差异（P<0.05~0.01）。结论加味益肾活血方可明显改善CKD患者肠道微生态紊乱状态，同时可改善CKD患者的临床症状、保护肾脏功能、改善微炎症状态，效果显著。
- 慢性肾脏病 /
- 中医药治疗 /
- 肠-肾轴学说 /
- 肠道微生态 /
- 微炎症
Abstract: OBJECTIVE To observe the effects of Yishen Huoxue decoction on intestinal microecology in patients with chronic kidney disease stage Ⅴ (CKD5). METHODS The non-dialysis patients in Lishui People's Hospital with deficiency of spleen and kidney qi and obstruction of dampness and blood stasis were randomly divided into two groups: 45 cases for the treatment group and 38 cases for the control group. The control group received routine treatment while the treatment group was given modified Yishen Huoxue decoction on the basis of routine treatment. After 8 weeks， blood samples and fecal samples of CKD patients were collected， and lactobacillus， bifidobacterium and escherichia coli， bacterial concentration of enterococcus faecalis in feces were detected by PCR. Routine biochemical parameters， including hemoglobin (Hb)， total protein (TP)， albumin (Alb)， serum creatinine (Scr)， blood urea nitrogen (BUN) and so forth were measured by automatic biochemical analyzer. ELISA method was used to detect the concentration of microinflammatory indexes. The changes of main symptom scores， renal function， microinflammatory indexes and intestinal microecology before and after treatment in the two groups were analyzed. RESULTS After treatment， the level of Scr and BUN in the treatment group decreased， along with the concentrations of hypersensitive c-reactive protein (hs-CRP)， interleukin-6 (IL-6) and tumor necrosis factor (TNF-α) (P<0.05)， which were significantly different from those in the control group (P<0.05， P<0.01). Main symptom scores in the two groups both decreased (P<0.05)， but the treatment group was superior to the control group (P<0.05，P<0.01). In the treatment group， the concentration of beneficial bacteria such as lactobacillus and bifidobacterium significantly increased (P<0.05)， while the harmful bacteria in the intestinal tract such as escherichia coli and enterococcus faecalis significantly decreased (P<0.05)， which were significantly different from those in the control group (P<0.05， P<0.01). CONCLUSION Tonifying the spleen and kidney and unblocking the bowels and discharging turbidity on intestinal microecology can conspicuously improve CKD patients' intestinal microecological disorder and their clinical symptoms， protect the renal function and improve the microinflammatory state with remarkable effects.
- chronic kidney disease /
- traditional Chinese medicine therapy /
- intestinal-kidney axis theory /
- intestinal microecology /
- microinflammation

HTML全文

参考文献(12)

[1]	FORT J. Chronic renal failure:A cardiovascular risk factor[J].Kidney Int， 2005，99:25-29.
[2]	ZHANG L， WANG F， WANG L， et al. Prevalence of chronic kidney disease in China:a cross-sectional survey[J]. Lancet，2012，379（9818）:815-822.
[3]	MEIJERS BK， EVENEPOEL P. The gut-kidney axis: indoxyl sulfate， p-cresyl sulfate and CKD progression[J]. Nephrol Dial Transplant，2011，26(3):759.
[4]	VAZIRI ND， ALONG J， PAHL M， et al. Chronic kidney disease alters intestinal microbial flora[J]. Kidney Int，2013，83:308-315.
[5]	WONG J， PICENO YM， DESANTIS TZ， et al. Expansion of urease- and uricase-containing， indole- and p-cresol-forming and contraction of short chain fatty acid-producing intestinal microbiota in ESRD[J]. Am J Nephrol， 2014，39(3):230-237.
[6]	ARMANI RC， RAMEZANI A， YASIR A， et al. Cut microbiome in chronis kidney disease[J].Translat Res，2017，19(4):29.
[7]	王海燕．慢性肾脏病及透析的临床实践指南[M].北京：人民卫生出版社，2005:22-23.
[8]	中药新药临床研究指导原则（试行）[S]. 北京:中国医药科技出版社，2002:36-39.
[9]	SKEIROV I， RUSSELL SL， ANTUNES LC， et al. Gut microbiota in health and disease[J].Physiol Rev，2010，90(4):859-904.
[10]	SANDEK A， RAUCHHAUS M， ANKER SD， et al. the emerging role of the gut in chronic heart failure[J].Curr Opin Clin Nutr Metab Care， 2008，11(3):632-639.
[11]	MAFRA D，FOUQUE D．Gut microbiota and inflammation in chronic kidney disease patients[J].Clin Kidney J，2015，8(3):332-334.
[12]	MAFRA D，LOBO JC，BARROS AF，et al．Role of altered intestinal microbiota in systemic inflammation and cardiovascular disease in chronic kidney disease[J]．Future Microbiol，2014，9(3):399-410．